Dupilumab Improved Esophageal Function in Eosinophilic Esophagitis
A trial showed that adults with EoE experienced increased esophageal flexibility after treatment with dupilumab.
Updated on Oct. 12, 2026 in Asthma
Live Poll
Do you trust pharmaceutical treatments to replace the need for traditional physical medical procedures?
In the phase 4 REMODEL trial, researchers found that dupilumab increased esophageal distensibility in adults with eosinophilic esophagitis compared to a placebo. These findings offer potential insights for adults managing structural esophageal changes related to this condition.
Why it matters
This trial was designed to test whether dupilumab can reverse structural esophageal damage caused by eosinophilic esophagitis without the need for mechanical dilation. By potentially improving esophageal caliber, the treatment aims to address the long-term narrowing that affects many patients with this chronic inflammatory disease.
In a 24-week phase 4 randomized trial of 69 adults, dupilumab treatment led to a 1.28 mm mean increase in esophageal distensibility plateau compared to -0.01 mm in the placebo group. Participants were prohibited from undergoing esophageal dilation throughout the study period.
The players
University of North Carolina
An academic institution serving as the home base for the lead researcher of the REMODEL trial.
The details
Researchers measured esophageal distensibility using an endoluminal functional lumen imaging probe to assess how well the esophagus expands. The study randomized participants into treatment and control groups to isolate the drug's effect on esophageal tissue structure without the confounding factor of mechanical dilation. Dupilumab also reduced the total EoE Endoscopic Reference Score by -4.96 compared to placebo, suggesting a potential for reversing structural remodeling.
Timeline
The primary trial period lasted for 24 weeks.
Trial results were presented at an ACG meeting on October 9-14, 2026.
An open-label extension study is planned for a 2-year duration.
Health Landscape
The REMODEL trial marks a shift from traditional mechanical symptom management toward potentially reversing structural tissue changes in eosinophilic esophagitis. This development follows recent trends in monoclonal antibody research aimed at addressing the underlying inflammatory drivers of chronic esophageal disease.
If you have been diagnosed with eosinophilic esophagitis, the findings regarding esophageal flexibility and endoscopic scores are worth discussing with your gastroenterologist. This research specifically highlights outcomes for adults, providing a basis for conversations about whether systemic treatments may reduce the need for repeat mechanical dilation procedures.
The takeaway
This study indicates that monoclonal antibody therapy may help restore esophageal tissue function in patients with eosinophilic esophagitis. Patients should track persistent swallowing difficulties and discuss with a physician whether their current treatment plan adequately addresses structural esophageal changes.
What happens next
A 2-year open-label extension study is underway to determine if esophageal caliber continues to improve without dilation, with additional data on epithelial barrier function expected at an upcoming European gastroenterology meeting.
Further reading
For more information on managing chronic inflammatory airway and digestive conditions, visit the Asthma section.
More information
Review the full details of the REMODEL trial clinical study information for more on the study design.
Source note: This article includes information reported by Hcplive.
Live Poll
Do you trust pharmaceutical treatments to replace the need for traditional physical medical procedures?
